Incyte SEC filings, summarized
We read every Incyte 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track INCY in your inbox
Add Incyte to your watchlist — free, every morning.
Recent filings
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and an Interactive XBRL cover page (Exhibit 104).…
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J. Cagnoni → President, Incyte & Global Head of R&D; Steven H. Stein → EVP, Chief Medical…
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg for metastatic NSCLC + platinum chemo. CRL cites…
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page Interactive XBRL also filed (Exhibit 104). $INCY…
Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…
Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY 2025 financial results for the period ended Dec 31,…
Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.
Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025. Former Chairman & CEO; board member since 2014. 8‑K shows no replacement named. $INCY 👋…